NeuroVive Pharmaceutical AB Interim report January – September 2018
KL1333 approved for phase I clinical trialImportant events January-September 2018 · NeuroVive’s genetic mitochondrial disease drug candidate KL1333 mechanism of action published in scientific journal · NeuroVive receives positive FDA feedback on its NeuroSTAT TBI development plan · NeuroVive’s NVP015 program will be supported through award of major research grant to Children’s Hospital of Philadelphia · NeuroVive and Yungjin reports positive KL1333 phase I clinical study results · KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases ·